Researchers developed the crossNN AI model that classifies over 170 cancer types from DNA methylation data, achieving over 97% accuracy and enabling non-invasive diagnosis from liquid biopsies and tissue samples.
Key Details
- 1crossNN is a simple, explainable neural network AI trained on 8,000+ reference tumors and tested on 5,000+ tumors.
- 2Achieved 99.1% accuracy for brain tumor diagnosis; 97.8% accuracy across more than 170 tumor types from all organs.
- 3Uses DNA methylation profiles obtained from tissue or body fluids (e.g., cerebrospinal fluid), enabling some diagnoses to avoid surgical biopsies.
- 4Proven more accurate than previous AI solutions for tumor classification.
- 5The method is being prepared for clinical trials at all eight sites of the German Cancer Consortium.
- 6crossNN's workflow is fully explainable, meeting a key regulatory requirement for clinical adoption.
Why It Matters
crossNN demonstrates the potential of AI-driven, minimally invasive tumor diagnostics, which could complement imaging in cases where biopsy is too risky or impractical. Such models can improve diagnostic precision, reduce patient morbidity, and streamline selection of personalized treatments, impacting radiology workflows and multidisciplinary cancer care.
Source
EurekAlert
Related News
•EurekAlert
AI Model Predicts Growth Spurts from Pediatric Neck X-rays for Orthodontics
Korean researchers developed an AI system (ARNet-v2) that predicts children's growth spurts from neck X-rays to enhance orthodontic treatment planning.
•EurekAlert
Dana-Farber Showcases AI and Clinical Trial Advances at ESMO 2025
Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
•EurekAlert
Einstein College Awarded $18M NIH Grant to Develop AI Tools for Mental Health Crisis Prediction
Albert Einstein College of Medicine received an $18 million NIH grant to create AI-based tools for predicting mental health crises using cognitive monitoring.